Us Pharmaceutical And Biotech Correspondent
Oliver Barnes is a US pharmaceutical and biotech correspondent at the Financial Times. He focuses on scientific innovation, blockbuster drugs, and access to healthcare, while also having a background in covering gambling, tobacco, and hospitality industries. Oliver's work has been featured in notable publications including The Irish Times, The Manila Times, and Yahoo Finance.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Oliver Barnes covers a variety of topics related to the business sector, including investments, gambling, restaurants, and media. He also shows interest in sports and entertainment news. His articles often include private sector announcements as well as government announcements and press releases.
To effectively reach out to Oliver with pitches or insights, consider offering exclusive information about industry trends or market movements within the UK or providing expert commentary on developments affecting businesses in these sectors. If you have access to insider knowledge about companies' financial performances or strategic moves in the UK's business landscape, your pitch is likely to resonate with him.
When reaching out regarding sporting events or entertainment news related to businesses (e.g., sponsorships), ensure that your content aligns with his coverage focus on the national level within the United Kingdom.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Oliver Barnes, Sujeet Indap
All-cash takeover will be one of the biggest gaming deals in years
By: Oliver Barnes
First substantial acquisition under new CEO is bet on eventual recovery in property sector
By: Oliver Barnes
Vimal Kapur is presiding over a three-way split that will usher in the end of corporate America’s conglomerate era
Midsized drug manufacturers are supplementing pipelines and scaling up in competition with Big Pharma
By: Oliver Barnes, Aanu Adeoye, James Fontanella-Khan
A deal will rank as one of UK drugmaker’s biggest as biotech M&A activity has enjoyed an upswing this year
By: Stephanie Findlay, Jamie Smyth, Oliver Barnes
Speculation of a looming consolidation wave mounts in the heartland of the US shale oil patch
By: Oliver Barnes, Patrick Temple-West
Buyout comes amid an uptick in biotech dealmaking as Big Pharma seeks to bolster its drug pipelines
By: Aaron Kirchfeld, Oliver Barnes, Ivan Levingston
Purchase of Dallas-based construction firm, which has over $8bn enterprise value, would be largest by Irish company
By: Oliver Barnes
Irish company closes in on purchase of Dallas-based construction firm with market capitalisation of almost $7bn
By: Oliver Barnes, Suzi Ring, Sujeet Indap, James Fontanella-Khan
Former Kirkland & Ellis partner helped turn firm into a restructuring powerhouse
